Key takeaways
Emtriva (emtricitabine) and Triumeq (abacavir/dolutegravir/lamivudine) are both medications used to treat HIV, but they belong to different classes and have distinct characteristics. Emtriva is a nucleoside reverse transcriptase inhibitor (NRTI) that is used in combination with other HIV medications, while Triumeq is a single-tablet regimen that combines three antiretrovirals: abacavir, dolutegravir, and lamivudine. Emtriva is available as a capsule and an oral solution, and it is typically taken once a day. Triumeq is also taken once a day but is available as a tablet or a dissolvable tablet for oral suspension. Emtriva is often used in combination tablets for pre-exposure prophylaxis (PrEP), although it is not FDA-approved for this use on its own. Triumeq requires genetic testing before use due to the risk of a serious allergic reaction, and it is not recommended for people with severe liver problems. Common side effects of Emtriva include nausea and fatigue, while Triumeq can cause higher blood sugar levels and trouble sleeping. Triumeq also has more drug interactions, such as with antacids and certain seizure medications.
